Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality

Bone Marrow Transplantation

Volumn 22, Issue 1, 1998, Pages 79-85

  Schots, R ^a   Kaufman, L ^a   Van Riet, I ^a   Lacor, P ^a   Trullemans, F ^a   De Waele, M ^a   Van Camp, B ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Allogeneic BMT; CRP levels; Severe complications; Transplant related mortality

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GROWTH FACTOR; MELPHALAN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTEREMIA; ENDOTHELIAL LEAKAGE SYNDROME; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION; REGRESSION ANALYSIS;

EID: 0031870957     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701286     Document Type: Article

References (21)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Davies SM, Wagner JE, Weisdorf DJ et al. Unrelated donor bone marrow transplantation for hematological malignancies-current status. Leuk Lymphoma 1996; 23: 221-226.
3. Höller E, Kolb HJ, Möller A et al. Increased serum levels of rumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
4. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein and fibrinogen. Sem Arthritis Rheum 1990; 20: 129-147.
5. Cohen J, Bayston K. Lymphokines and the acute-phase response in clinical bone marrow transplantation. Eur Cytokine Net 1990; 1: 251-255.
6. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
7. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985; 88: 215-238.
8. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138-1148.
9. Walker SA, Rogers TR, Riches PG et al. Value of serum C-reactive protein measurement in the management of bone marrow transplant recipients. Part I: early transplant period. J Clin Pathol 1984; 37: 1018-1021.
10. De Bel C, Gerritsen E, de Maaker G et al. C-reactive protein in the management of children with fever after allo BMT. Infection 1991; 19: 92-96.
11. Saarinen UM, Strandjord SE, Warkentin PI et al. Differentiation of presumed sepsis from acute graft-versus-host disease by C-reactive protein and serum total IgE in bone marrow transplant recipients. Transplantation 1987; 44: 540-546.
12. Sheldon J, Riches PG, Soni N et al. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clin Chem 1991; 37: 2038-2042.
13. Schwaighofer H, Herold M, Schwarz T et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994; 58: 430-436.
14. Chasty RC, Lamb WR, Gallati H et al. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331-336.
15. Donnelly JP, Muus P, Horrevorts AM et al. Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scand J Inf Dis 1993; 25: 43-50.
16. Steffen M, Durken M, Pichlmeier U et al. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment. Bone Marrow Transplant 1996; 18: 301-307.
17. Castell JV, Gomez-Lechon M J, David M et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186.
18. Van Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990; 8: 253-278.
19. Beutler B, Cerami A. The biology of cachectin/TNF-alpha as primary mediator of the host response. Ann Rev Immunol 1989; 7: 625-655.
20. Vachino G, Gelfand JA, Atkins MB et al. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 1991; 78: 2505-2513.
21. Wolbink GJ, Brouwer MC, Buysman S et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement - C-reactive protein complexes. J Immunol 1996; 157: 473-479.